Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Front Bioeng Biotechnol ; 10: 840939, 2022.
Article in English | MEDLINE | ID: mdl-35372322

ABSTRACT

Collagens are the major structural component in animal extracellular matrices and are critical signaling molecules in various cell-matrix interactions. Its unique triple helical structure is enabled by tripeptide Gly-X-Y repeats. Understanding of sequence requirements for animal-derived collagen led to the discovery of prokaryotic collagen-like protein in the early 2000s. These prokaryotic collagen-like proteins are structurally similar to mammalian collagens in many ways. However, unlike the challenges associated with recombinant expression of mammalian collagens, these prokaryotic collagen-like proteins can be readily expressed in E. coli and are amenable to genetic modification. In this review article, we will first discuss the properties of mammalian collagen and provide a comparative analysis of mammalian collagen and prokaryotic collagen-like proteins. We will then review the use of prokaryotic collagen-like proteins to both study the biology of conventional collagen and develop a new biomaterial platform. Finally, we will describe the application of Scl2 protein, a streptococcal collagen-like protein, in thromboresistant coating for cardiovascular devices, scaffolds for bone regeneration, chronic wound dressing and matrices for cartilage regeneration.

2.
Am J Hum Genet ; 109(4): 601-617, 2022 04 07.
Article in English | MEDLINE | ID: mdl-35395208

ABSTRACT

Neurodevelopmental disorders are highly heterogenous conditions resulting from abnormalities of brain architecture and/or function. FBXW7 (F-box and WD-repeat-domain-containing 7), a recognized developmental regulator and tumor suppressor, has been shown to regulate cell-cycle progression and cell growth and survival by targeting substrates including CYCLIN E1/2 and NOTCH for degradation via the ubiquitin proteasome system. We used a genotype-first approach and global data-sharing platforms to identify 35 individuals harboring de novo and inherited FBXW7 germline monoallelic chromosomal deletions and nonsense, frameshift, splice-site, and missense variants associated with a neurodevelopmental syndrome. The FBXW7 neurodevelopmental syndrome is distinguished by global developmental delay, borderline to severe intellectual disability, hypotonia, and gastrointestinal issues. Brain imaging detailed variable underlying structural abnormalities affecting the cerebellum, corpus collosum, and white matter. A crystal-structure model of FBXW7 predicted that missense variants were clustered at the substrate-binding surface of the WD40 domain and that these might reduce FBXW7 substrate binding affinity. Expression of recombinant FBXW7 missense variants in cultured cells demonstrated impaired CYCLIN E1 and CYCLIN E2 turnover. Pan-neuronal knockdown of the Drosophila ortholog, archipelago, impaired learning and neuronal function. Collectively, the data presented herein provide compelling evidence of an F-Box protein-related, phenotypically variable neurodevelopmental disorder associated with monoallelic variants in FBXW7.


Subject(s)
F-Box-WD Repeat-Containing Protein 7 , Neurodevelopmental Disorders , Ubiquitination , F-Box-WD Repeat-Containing Protein 7/chemistry , F-Box-WD Repeat-Containing Protein 7/genetics , F-Box-WD Repeat-Containing Protein 7/metabolism , Germ Cells , Germ-Line Mutation , Humans , Neurodevelopmental Disorders/genetics , Proteasome Endopeptidase Complex/metabolism , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolism
4.
Hum Mutat ; 43(4): 461-470, 2022 04.
Article in English | MEDLINE | ID: mdl-35094443

ABSTRACT

PAX5 is a transcription factor associated with abnormal posterior midbrain and cerebellum development in mice. PAX5 is highly loss-of-function intolerant and missense constrained, and has been identified as a candidate gene for autism spectrum disorder (ASD). We describe 16 individuals from 12 families who carry deletions involving PAX5 and surrounding genes, de novo frameshift variants that are likely to trigger nonsense-mediated mRNA decay, a rare stop-gain variant, or missense variants that affect conserved amino acid residues. Four of these individuals were published previously but without detailed clinical descriptions. All these individuals have been diagnosed with one or more neurodevelopmental phenotypes including delayed developmental milestones (DD), intellectual disability (ID), and/or ASD. Seizures were documented in four individuals. No recurrent patterns of brain magnetic resonance imaging (MRI) findings, structural birth defects, or dysmorphic features were observed. Our findings suggest that PAX5 haploinsufficiency causes a neurodevelopmental disorder whose cardinal features include DD, variable ID, and/or ASD.


Subject(s)
Autism Spectrum Disorder , Intellectual Disability , Neurodevelopmental Disorders , Animals , Autism Spectrum Disorder/genetics , Haploinsufficiency , Humans , Intellectual Disability/diagnosis , Intellectual Disability/genetics , Mice , Neurodevelopmental Disorders/genetics , Neurodevelopmental Disorders/pathology , PAX5 Transcription Factor , Phenotype
5.
Mol Genet Genomic Med ; 9(6): e1689, 2021 06.
Article in English | MEDLINE | ID: mdl-33951346

ABSTRACT

OBJECTIVE: We determined the yield, genetic spectrum, and actual origin of de novo mutations (DNMs) for infantile spasms (ISs) in a Chinese cohort. The efficacy of levetiracetam (LEV) for STXBP1-related ISs was explored also. METHODS: Targeted sequencing of 153 epilepsy-related candidate genes was applied to 289 Chinese patients with undiagnosed ISs. Trio-based amplicon deep sequencing was used for all DNMs to distinguish somatic/mosaic mutations from germline ones. RESULTS: Total of 26 DNMs were identified from 289 recruited Chinese patients with undiagnosed ISs. Among them, 24 DNMs were interpreted as pathogenic mutations based on American College of Medical Genetics and Genomics guidelines, contributing to 8.3% (24/289) of diagnosis yield in the Chinese IS cohort. CDKL5 and STXBP1 are the top genes with recurrent DNMs, accounting for 3.1% (9/289) of yield. Further deep resequencing for the trio members showed that 22.7% (5/22) of DNMs are actually somatic in the proband or a parent. These somatic carriers presented milder seizure attacks than those with true germline DNMs. After treatment with LEV for half a year, three patients with DNM in STXBP1 showed improved clinical symptoms, including seizure-free and normal electroencephalogram, except for a patient with a second DNM in DIAPH3. SIGNIFICANCE: Our study confirmed the contribution and genetic spectrum of DNMs in Chinese IS patients. Somatic mutation account for a quarter of DNMs in IS cases. Treatment with LEV improved the prognosis of STXBP1-related ISs.


Subject(s)
Germ-Line Mutation , Mosaicism , Spasms, Infantile/genetics , Adolescent , Adult , Anticonvulsants/therapeutic use , Child , Child, Preschool , Drug Resistance , Female , Formins/genetics , Gene Frequency , Humans , Infant , Levetiracetam/therapeutic use , Male , Munc18 Proteins/genetics , Protein Serine-Threonine Kinases/genetics , Spasms, Infantile/drug therapy , Spasms, Infantile/pathology
6.
Hum Mol Genet ; 30(3-4): 135-148, 2021 04 26.
Article in English | MEDLINE | ID: mdl-33432339

ABSTRACT

Huntington's disease pathogenesis involves a genetic gain-of-function toxicity mechanism triggered by the expanded HTT CAG repeat. Current therapeutic efforts aim to suppress expression of total or mutant huntingtin, though the relationship of huntingtin's normal activities to the gain-of-function mechanism and what the effects of huntingtin-lowering might be are unclear. Here, we have re-investigated a rare family segregating two presumed HTT loss-of-function (LoF) variants associated with the developmental disorder, Lopes-Maciel-Rodan syndrome (LOMARS), using whole-genome sequencing of DNA from cell lines, in conjunction with analysis of mRNA and protein expression. Our findings correct the muddled annotation of these HTT variants, reaffirm they are the genetic cause of the LOMARS phenotype and demonstrate that each variant is a huntingtin hypomorphic mutation. The NM_002111.8: c.4469+1G>A splice donor variant results in aberrant (exon 34) splicing and severely reduced mRNA, whereas, surprisingly, the NM_002111.8: c.8157T>A NP_002102.4: Phe2719Leu missense variant results in abnormally rapid turnover of the Leu2719 huntingtin protein. Thus, although rare and subject to an as yet unknown LoF intolerance at the population level, bona fide HTT LoF variants can be transmitted by normal individuals leading to severe consequences in compound heterozygotes due to huntingtin deficiency.


Subject(s)
Gene Expression Regulation , Huntingtin Protein/genetics , Mutation , Neurodevelopmental Disorders/genetics , Amino Acid Sequence , Cell Line , Child , Child, Preschool , Female , Humans , Huntingtin Protein/chemistry , Huntingtin Protein/metabolism , Loss of Function Mutation , Male , Mutation, Missense , Neurodevelopmental Disorders/metabolism , Pedigree , Phenotype , RNA Splicing , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Alignment , Sequence Analysis, DNA
7.
HGG Adv ; 1(1)2020 Oct 22.
Article in English | MEDLINE | ID: mdl-33718894

ABSTRACT

Attention deficit hyperactivity disorder (ADHD) is a common and highly heritable neurodevelopmental disorder with poorly understood pathophysiology and genetic mechanisms. A balanced chromosomal translocation interrupts CTNND2 in several members of a family with profound attentional deficit and myopia, and disruption of the gene was found in a separate unrelated individual with ADHD and myopia. CTNND2 encodes a brain-specific member of the adherens junction complex essential for postsynaptic and dendritic development, a site of potential pathophysiology in attentional disorders. Therefore, we propose that the severe and highly penetrant nature of the ADHD phenotype in affected individuals identifies CTNND2 as a potential gateway to ADHD pathophysiology similar to the DISC1 translocation in psychosis or AUTS2 in autism.

8.
Eur J Hum Genet ; 27(9): 1398-1405, 2019 09.
Article in English | MEDLINE | ID: mdl-30979967

ABSTRACT

Clinical exome sequencing (CES) is increasingly being utilized; however, a large proportion of patients remain undiagnosed, creating a need for a systematic approach to increase the diagnostic yield. We have reanalyzed CES data for a clinically heterogeneous cohort of 102 probands with likely Mendelian conditions, including 74 negative cases and 28 cases with candidate variants, but reanalysis requested by clinicians. Reanalysis was performed by an interdisciplinary team using a validated custom-built pipeline, "Variant Explorer Pipeline" (VExP). This reanalysis approach and results were compared with existing literature. Reanalysis of candidate variants from CES in 28 cases revealed 1 interpretation that needed to be reclassified. A confirmed or potential genetic diagnosis was identified in 24 of 75 CES-negative/reclassified cases (32.0%), including variants in known disease-causing genes (n = 6) or candidate genes (n = 18). This yield was higher compared with similar studies demonstrating the utility of this approach. In summary, reanalysis of negative CES in a research setting enhances diagnostic yield by about a third. This study suggests the need for comprehensive, continued reanalysis of exome data when molecular diagnosis is elusive.


Subject(s)
Computational Biology/methods , Exome Sequencing , Genetic Testing , Alleles , Exome , Genetic Association Studies/methods , Genetic Predisposition to Disease , Genetic Testing/methods , Genotype , Humans , Male , Phenotype
9.
Ann Neurol ; 85(6): 921-926, 2019 06.
Article in English | MEDLINE | ID: mdl-30937933

ABSTRACT

SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921-926.


Subject(s)
Epilepsy, Generalized/diagnosis , Epilepsy, Generalized/genetics , Excitatory Amino Acid Transporter 2/genetics , Genetic Variation/genetics , Amino Acid Sequence , Ceftriaxone/therapeutic use , Child, Preschool , Epilepsy, Generalized/drug therapy , Excitatory Amino Acid Transporter 2/chemistry , Female , HEK293 Cells , Humans , Infant , Infant, Newborn , Male , Protein Structure, Secondary
10.
Eur J Hum Genet ; 27(7): 1081-1089, 2019 07.
Article in English | MEDLINE | ID: mdl-30778173

ABSTRACT

Hexokinase 1 (HK1) phosphorylates glucose to glucose-6-phosphate, the first rate-limiting step in glycolysis. Homozygous and heterozygous variants in HK1 have been shown to cause autosomal recessive non-spherocytic hemolytic anemia, autosomal recessive Russe type hereditary motor and sensory neuropathy, and autosomal dominant retinitis pigmentosa (adRP). We report seven patients from six unrelated families with a neurodevelopmental disorder associated with developmental delay, intellectual disability, structural brain abnormality, and visual impairments in whom we identified four novel, de novo missense variants in the N-terminal half of HK1. Hexokinase activity in red blood cells of two patients was normal, suggesting that the disease mechanism is not due to loss of hexokinase enzymatic activity.


Subject(s)
Erythrocytes , Hereditary Sensory and Motor Neuropathy , Hexokinase , Mutation, Missense , Pedigree , Adolescent , Adult , Child , Erythrocytes/enzymology , Erythrocytes/pathology , Female , Hereditary Sensory and Motor Neuropathy/enzymology , Hereditary Sensory and Motor Neuropathy/genetics , Hereditary Sensory and Motor Neuropathy/pathology , Hexokinase/genetics , Hexokinase/metabolism , Humans , Infant , Male , Retinitis Pigmentosa/enzymology , Retinitis Pigmentosa/genetics , Retinitis Pigmentosa/pathology
11.
Genet Med ; 21(8): 1827-1831, 2019 08.
Article in English | MEDLINE | ID: mdl-30643218

ABSTRACT

PURPOSE: Associations of psychiatric and psychological symptoms with homocystinuria (HCU) have been described in multiple reports. This retrospective study was undertaken to refine the psychological phenotype among HCU patients and identify biomedical markers that could be used for prediction of those psychiatric or psychological symptoms. METHODS: This study examines the prevalence of psychological symptoms within a sample of 25 patients with classical homocystinuria. RESULTS: Psychological symptoms were noted in 16 of the 25 patients in the sample (64%), including a high prevalence of both anxiety (32%) and depression (32%) and correlated with IQ < 85. There was no difference in the type or the number of psychological symptoms between those diagnosed from newborn screening and early treated and those treated after 2 years of age. CONCLUSION: The results support the possible role of homocysteine as a risk factor for psychological and psychiatric problems and cognitive deficits and suggest that earlier diagnosis and treatment may reduce risk of their occurrences. Although early treatment clearly prevented serious medical complications, psychological and psychiatric symptoms were not associated with medical complications, highlighting the need for continued investigation.


Subject(s)
Anxiety/diagnosis , Depression/diagnosis , Homocystinuria/diagnosis , Mental Disorders/diagnosis , Adolescent , Adult , Animals , Anxiety/physiopathology , Anxiety/psychology , Child , Depression/physiopathology , Depression/psychology , Disease Models, Animal , Female , Homocystinuria/physiopathology , Homocystinuria/psychology , Humans , Male , Mental Disorders/physiopathology , Mental Disorders/psychology , Phenotype , Retrospective Studies , Young Adult
12.
Eur J Med Genet ; 62(2): 137-143, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29960046

ABSTRACT

Genomic sequencing has allowed for the characterization of new gene-to-disease relationships, as well as the identification of variants in established disease genes in patients who do not fit the classically-described phenotype. This is especially true in rare syndromes where the clinical spectrum is not fully known. After a lengthy and costly diagnostic odyssey, patients with atypical presentations may be left with many questions even after a genetic diagnosis is identified. We present a 22-year old male with hypotonia, developmental delay, seizure disorder, and dysmorphic facial features who enrolled in our rare disease research center at 18 years of age, where exome sequencing revealed a novel, likely pathogenic variant in the OPHN1 gene. Through efforts by the study team and collaborations with the larger genetics community, contacts with other families with OPHN1 variants were eventually made, and outreach by these families expanded the patient network. This partnership between families and researchers facilitated the gathering of phenotypic information, allowing for comparison of clinical presentations among three new patients and those previously reported in the literature. These comparisons found previously unreported commonalities between the newly identified patients, such as the presence of otitis media and the lack of genitourinary abnormalities (i.e. hypoplastic scrotum, microphallus, cryptorchidism), which had been noted to be classic features of patients with OPHN1 variants. As genomic sequencing becomes more common, connecting patients with novel variants in the same gene will facilitate phenotypic analysis and continue to refine the clinical spectrum associated with that gene.


Subject(s)
Craniofacial Abnormalities/genetics , Cytoskeletal Proteins/genetics , Developmental Disabilities/genetics , GTPase-Activating Proteins/genetics , Mutation , Nuclear Proteins/genetics , Phenotype , Adult , Child , Child, Preschool , Craniofacial Abnormalities/pathology , Developmental Disabilities/pathology , Diagnosis, Differential , Genetic Testing , Humans , Male , Syndrome
13.
J Perinatol ; 38(9): 1125-1134, 2018 09.
Article in English | MEDLINE | ID: mdl-30076402

ABSTRACT

Infants who die within the first weeks to months of life may have genetic disorders, though many die without a confirmed diagnosis. Non-genetic conditions may also be responsible for unexplained infant deaths, and the diagnosis may be reliant upon studies performed in the peri-mortem period. Neonatologists, obstetricians, or pediatricians caring for these children and their families may be unsure of which investigations can and should be performed in the setting of a newborn or infant who is dying or has died. Recent advances in genomic sequencing technology may provide additional diagnostic options, though the interpretation of genetic variants discovered by this technique may be contingent upon clinical phenotype information that is obtained peri-mortem or upon autopsy. We have reviewed the current literature concerning the evaluation of an unexplained neonatal or infantile demise and synthesized a diagnostic approach, with a focus on the contribution of new and emerging genomic technologies.


Subject(s)
Genomics/methods , Sudden Infant Death/diagnosis , Autopsy , Humans , Infant , Infant Death/etiology , Infant, Newborn
14.
Hum Mol Genet ; 27(21): 3710-3719, 2018 11 01.
Article in English | MEDLINE | ID: mdl-30085106

ABSTRACT

Mitochondrial dynamics, including mitochondrial division, fusion and transport, are integral parts of mitochondrial and cellular function. DNM1L encodes dynamin-related protein 1 (Drp1), a member of the dynamin-related protein family that is required for mitochondrial division. Several de novo mutations in DNM1L are associated with a range of disease states. Here we report the identification of five patients with pathogenic or likely pathogenic variants of DNM1L, including two novel variants. Interestingly, all of the positions identified in these Drp1 variants are fully conserved among all members of the dynamin-related protein family that are involved in membrane division and organelle division events. This work builds upon and expands the clinical spectrum associated with Drp1 variants in patients and their impact on mitochondrial division in model cells.


Subject(s)
GTP Phosphohydrolases/genetics , Microtubule-Associated Proteins/genetics , Mitochondrial Diseases/enzymology , Mitochondrial Dynamics , Mitochondrial Proteins/genetics , Mutation , Cell Line , Child , DNA Mutational Analysis , Dynamins , Female , GTP Phosphohydrolases/physiology , Humans , Infant , Male , Microtubule-Associated Proteins/physiology , Mitochondrial Diseases/physiopathology , Mitochondrial Proteins/physiology
15.
Pediatrics ; 141(Suppl 5): S434-S438, 2018 04.
Article in English | MEDLINE | ID: mdl-29610167

ABSTRACT

Oxcarbazepine is an antiepileptic drug (AED) commonly used as a first-line treatment option for focal epilepsy. Several AEDs, including carbamazepine, oxcarbazepine, and phenytoin are associated with various delayed-hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, or toxic epidermal necrolysis. The Food and Drug Administration-approved label for oxcarbazepine currently presents information regarding a pharmacogenomic association with the HLA antigen allele HLA-B*15:02 and hypersensitivity reactions in certain ancestry groups with a high incidence of this allele. However, unlike carbamazepine, screening for the presence of this allele is not routinely recommended before administration of oxcarbazepine. In practice, even with carbamazepine, HLA antigen testing is not always performed before initiating treatment because of lack of physician awareness of the recommendations and because of the desire to initiate treatment without delay. We present the clinical course of a pediatric patient with focal epilepsy refractory to several AEDs who developed drug reaction with eosinophilia and systemic symptoms after oxcarbazepine administration. The pharmacogenomic testing for various HLA antigen alleles was performed post hoc, and results were evaluated for structural similarities between AEDs and their molecular associations with HLA antigen proteins. In addition, we review the population-wide prevalence of various hypersensitivity reactions to AEDs and associated HLA antigen alleles. Finally, we discuss the potential utility of preemptive pharmacogenomic screening of patients before pharmacological treatment of epilepsy to assess the risk of developing hypersensitivity reactions.


Subject(s)
Anticonvulsants/adverse effects , Drug Hypersensitivity Syndrome/etiology , Epilepsies, Partial/drug therapy , Gene Deletion , HLA-A Antigens/genetics , Microtubule-Associated Proteins/genetics , Neuropeptides/genetics , Oxcarbazepine/adverse effects , Alleles , Anticonvulsants/chemistry , Child , Cross Reactions , Doublecortin Domain Proteins , Doublecortin Protein , Drug Hypersensitivity Syndrome/genetics , Epilepsies, Partial/genetics , Female , Humans , Molecular Structure , Oxcarbazepine/chemistry
16.
Am J Med Genet A ; 176(4): 925-935, 2018 04.
Article in English | MEDLINE | ID: mdl-29436146

ABSTRACT

SATB2-associated syndrome (SAS) is an autosomal dominant disorder characterized by significant neurodevelopmental disabilities with limited to absent speech, behavioral issues, and craniofacial anomalies. Previous studies have largely been restricted to case reports and small series without in-depth phenotypic characterization or genotype-phenotype correlations. Seventy two study participants were identified as part of the SAS clinical registry. Individuals with a molecularly confirmed diagnosis of SAS were referred after clinical diagnostic testing. In this series we present the most comprehensive phenotypic and genotypic characterization of SAS to date, including prevalence of each clinical feature, neurodevelopmental milestones, and when available, patient management. We confirm that the most distinctive features are neurodevelopmental delay with invariably severely limited speech, abnormalities of the palate (cleft or high-arched), dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies. This comprehensive clinical characterization will help clinicians with the diagnosis, counseling and management of SAS and help provide families with anticipatory guidance.


Subject(s)
Genetic Association Studies , Genetic Predisposition to Disease , Genotype , Matrix Attachment Region Binding Proteins/genetics , Phenotype , Transcription Factors/genetics , Abnormalities, Multiple/diagnosis , Abnormalities, Multiple/genetics , Adolescent , Adult , Child , Child, Preschool , Facies , Female , Genetic Association Studies/methods , Humans , Infant , Inheritance Patterns , Male , Polymorphism, Single Nucleotide , Syndrome , Young Adult
17.
J Pediatr ; 196: 270-274.e1, 2018 05.
Article in English | MEDLINE | ID: mdl-29398060

ABSTRACT

OBJECTIVE: To study the utility of genetic evaluation and testing in patients with suspected fetal alcohol spectrum disorder (FASD). STUDY DESIGN: We performed a retrospective chart review of all patients (n = 36) referred for evaluation for suspected FASD to the genetics clinic at Boston Children's Hospital between January 2006 and January 2013. Records of all patients were reviewed to obtain the medical history, family history, examination findings, and investigations, including genetic testing. RESULTS: Of the 36 patients, definite prenatal exposure was documented in 69%. Eight patients did not fulfill clinical criteria for FASD. Chromosomal microarray analysis (CMA) detected 19 copy number variants (CNVs) in 14 patients. Among patients who fulfilled criteria for FASD and underwent CMA, pathogenic CNVs were detected in 3 patients (2q37del, 22q11.22dup, and 4q31.21del syndromes), giving a yield of 14.3%. All 3 patients had overlapping features between FASD and the genetic syndrome. CONCLUSION: Genetic testing, especially CMA, should be considered in patients referred for evaluation of FASD, as a significant proportion have a clinically significant CNV even when they fulfill diagnostic criteria for FASD spectrum.


Subject(s)
Fetal Alcohol Spectrum Disorders/genetics , Genetic Testing/methods , Prenatal Exposure Delayed Effects/epidemiology , Adolescent , Boston , Child , Child, Preschool , DNA Copy Number Variations , Developmental Disabilities/diagnosis , Developmental Disabilities/etiology , Developmental Disabilities/genetics , Female , Fetal Alcohol Spectrum Disorders/diagnosis , Humans , Infant , Infant, Newborn , Male , Pregnancy , Retrospective Studies
18.
J Neurogenet ; 31(1-2): 30-36, 2017.
Article in English | MEDLINE | ID: mdl-28460589

ABSTRACT

Pathogenic missense and truncating variants in the GABRG2 gene cause a spectrum of epilepsies, from Dravet syndrome to milder simple febrile seizures. In most cases, pathogenic missense variants in the GABRG2 gene segregate with a febrile seizure phenotype. In this case series, we report a recurrent, de novo missense variant (c0.316 G > A; p.A106T) in the GABRG2 gene that was identified in five unrelated individuals. These patients were described to have a more severe phenotype than previously reported for GABRG2 missense variants. Common features include variable early-onset seizures, significant motor and speech delays, intellectual disability, hypotonia, movement disorder, dysmorphic features and vision/ocular issues. Our report further explores a recurrent pathogenic missense variant within the GABRG2 variant family and broadens the spectrum of associated phenotypes for GABRG2-associated disorders.


Subject(s)
Abnormalities, Multiple/pathology , Mutation, Missense , Receptors, GABA-A/genetics , Severity of Illness Index , Abnormalities, Multiple/genetics , Adolescent , Child , Epilepsy/genetics , Epilepsy/pathology , Female , Humans , Infant , Intellectual Disability/genetics , Intellectual Disability/pathology , Male , Motor Disorders/genetics , Motor Disorders/pathology , Movement Disorders/genetics , Movement Disorders/pathology , Muscle Hypotonia/genetics , Muscle Hypotonia/pathology , Pedigree , Phenotype , Speech Disorders/genetics , Speech Disorders/pathology
19.
J Child Adolesc Psychopharmacol ; 27(10): 850-863, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28475355

ABSTRACT

OBJECTIVES: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, in addition to being the commonest diagnosable cause of autism. The identification of the biochemical mechanism underlying this disorder has provided amenable targets for therapy. This review aims to provide an overview of investigational drug therapies for FXS. METHODS: The authors carried out a search of clinical and preclinical trials for FXS in PubMed and on the U.S. National Institutes of Health index of clinical trials ( www.clinicaltrials.gov ). We limited our review to Phase II trials or more preliminary and reviewed the associated publications for these studies, complemented by a review of the literature on PubMed. RESULTS: The review of the preclinical, Phase I, and Phase II trials of agents with therapeutic potential in FXS revolves around an understanding of the putative pathways in the pathogenesis of FXS. While there is significant overlap between some of these pathways, the agents can be categorized as modulators of the metabotropic glutamate receptor system, GABAergic agents, and miscellaneous modulators affecting other pathways. CONCLUSION: As trials involving agents targeting different aspects of the molecular biology proceed, common themes have emerged. With the great hope came great disappointment as the initial trials failed to demonstrate sufficient significance. In particular, the differences in outcome between the animal models and humans have highlighted the unique challenges of carrying out trials in these cognitively and behaviorally challenged individuals, as well as a dearth of clinically relevant outcome measures for use in medication trials. However, in reviewing and reframing the studies of the last decade, many important lessons have been learned, which will ultimately have a greater impact on therapeutic research in the field of developmental delay as a whole.


Subject(s)
Drugs, Investigational/therapeutic use , Fragile X Syndrome/diagnosis , Fragile X Syndrome/drug therapy , Animals , Clinical Trials as Topic/methods , Fragile X Syndrome/metabolism , Humans , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...